Richard P. Baum is the President of the International Centers for Precision Oncology (ICPO) Academy. He also serves as a Consultant at Curanosticum Wiesbaden-Frankfurt, Germany. Professor Baum is a clinician-scientist who has been involved in the use of radiolabeled monoclonal antibodies for imaging and therapy since the 1980s, in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors since 1997, and in PSMA radioligand therapy since 2013 (he administered the world's first 177Lu-PRLT). In October 2019, he and his team performed the world's first Peptide-targeted Radiotherapy (PTRT) using 177Lu-FAP. Professor Baum has received numerous other honors and awards and has published extensively (H-Index: 73).